Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 196

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

Open access
Gough, Sheryl M., Flanagan, John J., Teh, Jessica, Andreoli, Monica, Rousseau, Emma, Pannone, Melissa, Bookbinder, Mark, Willard, Ryan, Davenport, Kim, Bortolon, Elizabeth, Cadelina, Gregory, Gordon, Debbie, Pizzano, Jennifer, Macaluso, Jennifer, Soto, Leofal, Corradi, John, Digianantonio, Katherine, Drulyte, Ieva, Morgan, Alicia, Quinn, Connor, Békés, Miklós, Ferraro, Caterina, Chen, Xin, Wang, Gan, Dong, Hanqing, Wang, Jing, Langley, David R., Houston, John, Gedrich, Richard, Taylor, Ian C. · 2024 · Clinical Cancer Research

Abstract

Purpose: Estrogen receptor (ER) alpha signaling is a known driver of ER-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2−) breast cancer. Combining endocrine therapy (ET) such as fulvestrant with CDK4/6, mTOR, or PI3K inhibitors has become a central strategy in the treatment of ER+ advanced breast cancer. However, suboptimal ER inhibition and resistance resulting from the ESR1 mutation dictates that new therapies are needed. Experimental Design: A medicinal chemistry campaign identified vepdegestrant (ARV-471), a selective, orally bioavailable, and potent small molecule PROteolysis-TArgeting Chimera (PROTAC) degrader of ER. We used biochemical and intracellular target engagement assays to demonstrate the mechanism of action of vepdegestrant, and ESR1 wild-type (WT) and mutant ER+ preclinical breast cancer models to demonstrate ER degradation-mediated tumor growth inhibition (TGI). Results: Vepdegestrant induced ≥90% degradation of wild-type and mutant ER, inhibited ER-dependent breast cancer cell line proliferation in vitro, and achieved substantial TGI (87%–123%) in MCF7 orthotopic xenograft models, better than those of the ET agent fulvestrant (31%–80% TGI). In the hormone independent (HI) mutant ER Y537S patient-derived xenograft (PDX) breast cancer model ST941/HI, vepdegestrant achieved tumor regression and was similarly efficacious in the ST941/HI/PBR palbociclib-resistant model (102% TGI). Vepdegestrant-induced robust tumor regressions in combination with each of the CDK4/6 inhibitors palbociclib, abemaciclib, and ribociclib; the mTOR inhibitor everolimus; and the PI3K inhibitors alpelisib and inavolisib. Conclusions: Vepdegestrant achieved greater ER degradation in vivo compared with fulvestrant, which correlated with improved TGI, suggesting vepdegestrant could be a more effective backbone ET for patients with ER+/HER2− breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-23-3465

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 196

Metadata

Authors
Gough, S. M., Flanagan, J. J., Teh, J., Andreoli, M., Rousseau, E., Pannone, M., Bookbinder, M., Willard, R., Davenport, K., Bortolon, E., Cadelina, G., Gordon, D., Pizzano, J., Macaluso, J., Soto, L., Corradi, J., Digianantonio, K., Drulyte, I., Morgan, A., Quinn, C., Békés, M., Ferraro, C., Chen, X., Wang, G., Dong, H., Wang, J., Langley, D. R., Houston, J., Gedrich, R., & Taylor, I. C.
Venue
Clinical Cancer Research
Published
2024-05-31
Volume
30
Issue
16
Pages
3549-3563
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4399212684
Cited by
196
References
17
FWCI
50.01
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-23-3465
The paper
Gough, S. M., Flanagan, J. J., Teh, J., Andreoli, M., Rousseau, E., Pannone, M., Bookbinder, M., Willard, R., Davenport, K., Bortolon, E., Cadelina, G., Gordon, D., Pizzano, J., Macaluso, J., Soto, L., Corradi, J., Digianantonio, K., Drulyte, I., Morgan, A., . . . Taylor, I. C. (2024). Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-23-3465

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.